Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jun 15;79(12):997-1005.
doi: 10.1016/j.biopsych.2015.08.021. Epub 2015 Aug 29.

Reduced Brain Cannabinoid Receptor Availability in Schizophrenia

Mohini Ranganathan  1 , Jose Cortes-Briones  2 , Rajiv Radhakrishnan  2 , Halle Thurnauer  2 , Beata Planeta  3 , Patrick Skosnik  2 , Hong Gao  4 , David Labaree  4 , Alexander Neumeister  5 , Brian Pittman  3 , Toral Surti  6 , Yiyun Huang  4 , Richard E Carson  4 , Deepak Cyril D'Souza  2
Affiliations

Reduced Brain Cannabinoid Receptor Availability in Schizophrenia

Mohini Ranganathan et al. Biol Psychiatry. .

Abstract

Background: Several lines of evidence suggest the presence of abnormalities in the endocannabinoid (eCB) system in schizophrenia (SCZ). However, there are limited in vivo measures of the eCB system in SCZ.

Methods: Twenty five male SCZ subjects (SCZs) (18 antipsychotic treated and 7 antipsychotic free) were compared with 18 age-matched male healthy control subjects (HCs). Subjects underwent one positron emission tomography scan each with the cannabinoid receptor-1 (CB1R) selective radiotracer [(11)C]OMAR on the high resolution research tomography scanner. Regional volume of distribution (VT) values were determined using kinetic modeling of positron emission tomography data as a measure of CB1R availability. Group differences in mean composite [(11)C]OMAR VT values were compared between SCZs and HCs. Exploratory comparisons of CB1R availability within 15 brain regions were also conducted. All analyses were covaried for age and body mass index.

Results: SCZs showed significantly (p = .02) lower composite [(11)C]OMAR VT relative to HCs (~12% difference, effect size d = .73). [(11)C]OMAR VT was significantly (all ps < .05) lower in SCZs in the amygdala, caudate, posterior cingulate cortex, hippocampus, hypothalamus, and insula. Composite [11]OMAR VT was HCs > antipsychotic treated SZCs > antipsychotic free SZCs. Furthermore, composite [(11)C]OMAR VT was greater in HCs than SCZ smokers (n = 11) and SCZ nonsmokers (n = 14).

Conclusions: CB1R availability is lower in male SCZ subjects compared with HCs. Furthermore, antipsychotics and tobacco use may increase CB1R availability in this population. The findings of the study provide further evidence supporting the hypothesis that alterations in the eCB system might contribute to the pathophysiology of SCZ.

Trial registration: ClinicalTrials.gov NCT01730781.

Keywords: Antipsychotics; CB(1)R; Cannabinoid; OMAR; Schizophrenia; Smoking.

PubMed Disclaimer

Conflict of interest statement

Disclosure: All other authors report no biomedical financial interests or potential conflicts of interest.

Figures

Figure 1
Figure 1. Grand Averaged CB1R availability in Schizophrenia Patients vs. Healthy Controls
Top row: HC averaged (n=21) of the distribution volume (VT; Innis et al., 2007) images computed using the multilinear analysis (MA1; Ichise et al., 2002) Middle row: SCZ averaged (n=25) of the distribution volume (VT; Innis et al., 2007) images computed using the multilinear analysis (MA1; Ichise et al., 2002) Bottom row: Aligned T1 MR image for anatomical reference
Figure 2
Figure 2. CB1R availability in Schizophrenia Patients vs. Healthy Controls
The figure shows the mean and standard error bars of [11C]OMAR Volume of Distribution (VT). Significant differences (p<0.05) between groups are indicated with *. Trend differences (p<0.06–0.1) between groups are indicated with #.
Figure 3
Figure 3. Effects of Antipsychotic Treatment on CB1R availability
The figure shows the mean and standard error bars of [11C]OMAR Volume of Distribution (VT). See text for statistically significant differences between 3 groups. *p = 0.025. #p = 0.07.
Figure 4
Figure 4. Effects of Tobacco Smoking on CB1R availability
The figure shows the mean and standard error bars of [11C]OMAR Volume of Distribution (VT). See text for statistically significant differences between 3 groups. *p = 0.006. #p = 0.096.
See this image and copyright information in PMC

Comment in

References

    1. Koethe D, Hoyer C, Leweke FM. The endocannabinoid system as a target for modelling psychosis. Psychopharmacology (Berl) 2009;206:551–561. - PubMed
    1. Fernandez-Espejo E, Viveros MP, Nunez L, Ellenbroek BA, Rodriguez de Fonseca F. Role of cannabis and endocannabinoids in the genesis of schizophrenia. Psychopharmacology (Berl) 2009;206:531–549. - PubMed
    1. D’Souza DC, Sewell RA, Ranganathan M. Cannabis and psychosis/schizophrenia: human studies. Eur Arch Psychiatry Clin Neurosci. 2009;259:413–431. - PMC - PubMed
    1. Sewell RA, Ranganathan M, D’Souza DC. Cannabinoids and psychosis. Int Rev Psychiatry. 2009;21:152–162. - PubMed
    1. Murray RM, Morrison PD, Henquet C, Di Forti M. Cannabis, the mind and society: the hash realities. Nat Rev Neurosci. 2007;8:885–895. - PubMed

Publication types

Associated data